Optimal dose of intravenous cyclophosphamide during remission induction therapy in ANCA-associated vasculitis: A retrospective cohort study of J-CANVAS

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

(2023) Bernhard Hellmich et al.   ANNALS OF THE RHEUMATIC DISEASES

Association between hypogammaglobulinaemia and severe infections during induction therapy in ANCA-associated vasculitis: from J-CANVAS study

(2023) Satoshi Omura et al.   RHEUMATOLOGY

Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening

(2022) Tingting Xu et al.   RMD Open

Incidence and temporal trend in risk factors of severe infections in ANCA-Glomerulonephritis patients.

(2021) Pierre Jourdain et al.   Kidney International Reports

Avacopan for the Treatment of ANCA-Associated Vasculitis

(2021) David R.W. Jayne et al.   NEW ENGLAND JOURNAL OF MEDICINE

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

(2021) Sharon A. Chung et al.   ARTHRITIS CARE & RESEARCH

Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study

(2020) Jens Rathmann et al.   RHEUMATOLOGY

Predicting severe infection and effects of hypogammaglobulinaemia during therapy with rituximab in rheumatic and musculoskeletal diseases

(2019) Md Yuzaiful Md Yusof et al.   Arthritis & Rheumatology

T-cell modulation by cyclophosphamide for tumour therapy

(2018) Ellyn Hughes et al.   IMMUNOLOGY

Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study

(2018) Liu Yang et al.   BMC Nephrology

Dose translation between laboratory animals and human in preclinical and clinical phases of drug development

(2018) Anroop Nair et al.   DRUG DEVELOPMENT RESEARCH

Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study

(2018) Dimitri Titeca-Beauport et al.   BMC Nephrology

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

(2016) M Yates et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy

(2015) A. Visentin et al.   HAEMATOLOGICA

Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy

(2015) A. Visentin et al.   HAEMATOLOGICA

Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older: Results of a Multicenter, Open-Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide-Based Induction Therapy

(2015) Christian Pagnoux et al.   Arthritis & Rheumatology

Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis

(2013) Kirsten de Groot   ANNALS OF INTERNAL MEDICINE

2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

(2012) J. C. Jennette et al.   ARTHRITIS AND RHEUMATISM

Long-term patient survival in ANCA-associated vasculitis

(2010) O. Flossmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis

(2009) M. A. Little et al.   ANNALS OF THE RHEUMATIC DISEASES

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

(2008) C Mukhtyar et al.   ANNALS OF THE RHEUMATIC DISEASES